Francois Brisebois
Francois Brisbois is managing director and senior analyst at Oppenheimer & Co. Inc. covering biotechnology. Prior to joining Oppenheimer, he was a senior research analyst at Craig-Hallum Capital covering biotechnology and biopharmaceuticals. He previously worked at Laidlaw Capital Markets as a senior analyst covering biotechnology and specialty pharmaceuticals and started his Wall Street career at healthcare specialty firm Summer Street Research Partners. Brisebois holds a bachelor's degree in molecular biology from Colgate University and a Master of Science in pharmaceutical sciences from University of Montreal.
Recent Quotes
"DRRX already exceeded enrollment in its Phase 1b NASH trial."
—
Francois Brisebois, Craig-Hallum Capital
(3/4/20)
more >
"DRRX's Phase 2a DUR-928 study in AH showed efficacy data and safety."
—
Francois Brisebois, Laidlaw & Company
(9/18/19)
more >
"Recent developments at DRRX led to a substantial influx of capital."
—
Francois Brisebois, Laidlaw & Company
(8/2/19)
more >
"Its partnership with Gilead could add visibility to DRRX's DUR-928."
—
Francois Brisebois, Laidlaw & Company
(7/22/19)
more >
"DRRX's capital raise takes care of financing overhang on the stock."
—
Francois Brisebois, Laidlaw & Company
(6/27/19)
more >
"We are encouraged by DRRX's clinical timeline remaining on track."
—
Francois Brisebois, Laidlaw & Company
(5/13/19)
more >
"DRRX's current valuation is an interesting buying opportunity."
—
Francois Brisebois, Laidlaw & Company
(3/8/19)
more >
"We are encouraged by DRRX's decision to fully respond to the CRL."
—
Francois Brisebois, Laidlaw & Company
(2/28/19)
more >
